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Introduction: Nowadays, two strategies are available for the management of the
clinically negative neck in early-stage (cT1-2N0) oral squamous cell carcinoma (OSCC):
elective neck dissection (END) and sentinel lymph node biopsy (SLNB). SLNB stages
both the ipsilateral and the contralateral neck in early-stage OSCC patients, whereas the
contralateral neck is generally not addressed by END in early-stage OSCC not involving
the midline. This study compares both incidence and hazard of contralateral regional
recurrences (CRR) in those patients who underwent END or SLNB.
Materials and Methods: A retrospective multicenter cohort study, including 816
lateralized or paramedian early-stage OSCC patients, staged by either unilateral or
bilateral END (n = 365) or SLNB (n = 451).
Results: The overall rate of occult contralateral nodal metastasis was 3.7% (30/816);
the incidence of CRR was 2.5% (20/816). Patients who underwent END developed CRR
during follow-up more often than those who underwent SLNB (3.8 vs. 1.3%; p = 0.018).
Moreover, END patients had a higher hazard for developing CRR than SLNB patients (HR
= 2.585; p = 0.030). In addition, tumor depth of invasion was predictive for developing
CRR (HR = 1.922; p = 0.009). Five-year disease-specific survival in patients with
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CRR was poor (42%) compared to patients in whom occult contralateral nodal
metastases were detected by SLNB or bilateral END (88%), although not statistically
different (p = 0.066).
Conclusion: Our data suggest that SLNB allows for better control of the contralateral
clinically negative neck in patients with lateralized or paramedian early-stage OSCC,
compared to END as performed in a clinical setting. The prognosis of those in whom
occult contralateral nodal metastases are detected at an earlier stage may be favorable
compared to those who eventually develop CRR, which highlights the importance of
adequate staging of the contralateral clinically negative neck.
Keywords: mouth neoplasms, sentinel lymph node biopsy, neck dissection, lymphatic metastasis, contralateral,
recurrence, survival
INTRODUCTION
In patients with early-stage (cT1-2N0) oral squamous cell
carcinoma (OSCC), occult metastases are present in 20–30%
of patients with a clinically negative neck, despite advanced
diagnostic imaging modalities (1–3).
As watchful-waiting in these patients has been associated
with a poor prognosis, especially when compared to those in
whom the clinically negative neck was electively treated (1), two
strategies are available for management of the clinically negative
neck in early-stage OSCC: elective neck dissection (END) and
sentinel lymph node biopsy (SLNB) (3–6). Although END is
considered the best approach by many (5), SLNB has proven to
reliably stage the clinically negative neck in early-stage OSCC
with a pooled sensitivity and negative predictive value of 87
and 94%, respectively (4, 7–9). While END has the benefit
of being a single-stage procedure, without need for specific
facilities (e.g., nuclearmedicine, advanced histopathology), SLNB
is less invasive for the 70–80% of patients without metastatic
neck involvement and has overall lower morbidity rates, better
quality of life, and lower health care costs compared to
END (10–13).
Furthermore, SLNB allows assessment of individual lymphatic
drainage patterns and is able to detect aberrant drainage patterns
(14, 15). This feature is of particular benefit in OSCC, since
even lateralized OSCC occasionally metastasizes to contralateral
cervical lymph nodes [2.7% (95% CI 1.2–4.2%)] (8, 9, 14, 16–
21). Studies reported contralateral or bilateral lymphatic drainage
patterns in 13–23% of lateralized OSCC patients, as detected
during the SLNB procedure (8, 9, 14, 22).
Thus, SLNB stages the contralateral clinically negative neck
in (lateralized) early-stage OSCC patients as well, whereas the
contralateral clinically negative neck is generally not addressed
by END in early-stage OSCC not involving the midline (i.e.,
lateralized or paramedian tumors).
Although the reported incidence of contralateral lymph node
metastases in these patients is relatively low, underdiagnosis of
the contralateral clinically negative neck is undesirable, especially
since the presence of contralateral lymph node metastasis from
OSCC has been associated with poor disease-specific survival
(DSS) (16, 23, 24).
Therefore, this study aimed to assess whether SLNB allows
for better control of the contralateral neck as compared to END,
in early-stage OSCC not involving the midline. Accordingly,
this study compares both incidence and hazard of contralateral
regional recurrences (CRR) in those who underwent either END
or SLNB as performed in daily clinical practice. Furthermore,
this study compares the prognosis of those in whom occult
contralateral nodal metastases were detected at an earlier stage




This study abided the Declaration of Helsinki and was
approved by UMC Utrecht’s Ethics Committee (no. 17/766)
and all participating centers. The Internal Review Board waived
requirement for signed informed consent forms for all subjects
(4). Samples and data were handled according to General Data
Protection Regulation.
Patients
Patients without a history of head and neck cancer requiring
treatment of the neck (i.e., neck dissection, neck irradiation)
were included from five Dutch Head and Neck Cancer centers.
In these centers, SLNB is currently part of standard oncological
care in regard to staging the clinically negative neck in early-stage
OSCC patients. Data were extracted from two large retrospective
cohorts (END cohort and SLNB cohort), which have been
extensively described by den Toom et al. (4).
For this study, only patients with early-stage OSCC (cT1-2N0)
not involving the midline (i.e., lateralized or paramedian) were
included in this study (AJCC UICC TNM-staging 7th Edition).
Paramedian tumors were classified as tumors located adjacent
to, but not involving, the midline. In all patients, clinical nodal
staging was confirmed by palpation, imaging (i.e., ultrasound, CT,
and/or MRI), and, in case of suspected lymph nodes, ultrasound-
guided fine-needle aspiration cytology.
Patients who underwent unilateral END for tumors from
which the specific location was missing were included. In these
cases, it was estimated that performing unilateral END, instead
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FIGURE 1 | Flowchart for inclusion of patients in both the END cohort (n = 365) and the SLNB cohort (n = 451).
of bilateral END, was on the basis of non-involvement of the
midline. Patients who underwent bilateral END for confirmed
lateralized or paramedian early-stage OSCC were included
as well.
Patients were excluded if they underwent bilateral END for
tumors from which the specific location was missing, as there
was insufficient data to reliably assess whether the tumor involved
the midline.
Out of 887 patients (END n = 399, SLNB n = 488),
816 patients met the inclusion criteria (END n = 365, SLNB
n= 451) (Figure 1).
Elective Neck Dissection
The END cohort has been previously described by den Toom
et al. (4); early-stage OSCC patients who underwent END
between 1990 and 2015 were included in the END cohort.
END was performed as selective (level I–III/IV; n = 294)
or modified radical neck dissection (level I–V; n = 70).
Twenty-eight patients (7.7%) underwent bilateral END for
lateralized or paramedian early-stage OSCC. The decision
to perform either unilateral or bilateral END was made by
the treating physician. The indication for bilateral END was
on discretion of the treating physician and multidisciplinary
team. END was elected over watchful-waiting when tumor
depth of invasion (DOI) was estimated to be >4mm (25).
Neck dissection specimens were histopathologically assessed
using conventional hematoxylin–eosin staining on formalin-
fixed paraffin-embedded tissue.
Sentinel Lymph Node Biopsy
Early-stage OSCC patients who underwent SLNB between
2007 and 2018 were included in the SLNB cohort. SLNB was
performed according to European Association of Nuclear
Medicine and Sentinel European Node Trial joint practice
guidelines (26–28). SLNB was elected over watchful-waiting
irrespective of tumor DOI. In short, the SLNB procedure
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consisted of preoperative peritumoral injections with
technetium-99m [99mTc]-labeled nanocolloid (80–240 MBq),
followed by planar dynamic and static lymphoscintigraphy
including SPECT-CT imaging, in a 1- or 2-day protocol.
Intraoperative localization and extirpation of SLNs were
performed using a handheld gammaprobe. Harvested SLNs were
histopathologically assessed using step-serial sectioning (section
thickness 150–500µm) with hematoxylin–eosin staining and
immunohistochemistry (26, 29). In SLNB-negative patients,
a wait-and-scan policy was adopted, while SLNB-positive
patients underwent complementary neck treatment. The vast
majority of SLNB-positive patients underwent neck dissection as
complementary neck treatment (85.6%; 89/104). Seven patients
(6.7%) underwent complementary neck irradiation and three
patients (2.9%) underwent complementary chemoradiation due
to irradical resection of the primary tumor (n= 2) or presence of
extracapsular spread of nodal metastasis (n = 1). Radiotherapy
was employed only on the affected nodal basin in three patients,
whereas in the other seven patients, the side and levels involved
in neck irradiation were unknown.
CRR, pN2c and Occult Contralateral Nodal
Metastasis
Regional recurrences that occurred in the contralateral neck of
the initial primary tumor, within 5 years following treatment,
were regarded as event for CRR analyses. In addition, CRR in
the presence of ipsilateral regional recurrences were regarded
as event for CRR analyses as well. Regional recurrences in the
presence of local recurrence or second primary tumors were
excluded from final analyses, as differentiation between missed
nodal metastasis at initial diagnostic work-up and metastasis
developed from reseeding local recurrence is unfeasible.
Nodal metastasis detected in the contralateral neck of the
primary tumor at time of initial neck staging, by either SLNB or
bilateral END, was classified as pN2c, irrespective of the nodal
status of the ipsilateral neck.
Occult contralateral nodal metastasis was defined as lymph
node metastasis in the contralateral neck of the initial primary
tumor, which was detected by either SLNB or bilateral
END (i.e., pN2c) or which became clinically manifest during
follow-up (i.e., CRR).
Statistical Analysis
All data were analyzed with IBM SPSS Statistics Version
26.0. Data are expressed as mean ± SD for continuous
variables. Number of cases and percentages are presented for
categorical variables.
Independent samples t test was applied for parametric
continuous variables, Mann–Whitney U test was applied for
non-parametric continuous variables, and χ2 test was applied
for categorical variables. Fisher’s exact test was used to compare
categorical variables containing small number of cases (n ≤ 5).
Post-hoc testing was conducted in case of statistically significant
χ
2 test or Fisher’s exact test outcomes for categorical variables
with ≥3 groups.
For comparing 5-year DSS between patients with occult
contralateral nodal metastasis (i.e., pN2c, CRR) and those
without, Log-Rank test was conducted and Kaplan–Meier
survival curves were computed. Furthermore, 5-year DSS
were compared between patients in whom contralateral nodal
metastases were detected by SLNB or bilateral END (pN2c) and
those who eventually developed CRR during follow-up.
To assess independent predictors of CRR over time, Cox-
regression analysis was applied (Method: Backward Likelihood
Ratio). Variables that showed univariate association with
occult contralateral nodal metastasis (i.e., pN2c and/or CRR),
at a level of p ≤ 0.05, were included in the proportional
hazard regression model. Accordingly, covariates were neck
management (SLNB/END), initial ipsilateral pN+-status,
location of primary tumor (i.e., paramedian or lateralized), vaso-
invasive tumor growth, perineural tumor growth, and tumor
DOI. Included covariates were analyzed for multicollinearity;
variables with correlation of ≥0.5 were not included in
Cox-regression analysis (30).
Missing data were handled by pairwise deletion. A p-value of
<0.05 was regarded statistically significant.
RESULTS
The SLNB cohort contained a higher rate of tongue tumors (p <
0.001), whereas the END cohort contained a higher rate of floor-
of-mouth tumors (p = 0.008) (Table 1). The END cohort had a
higher rate of cT2-staged tumors (p < 0.001) and a higher rate of
tumors staged pT2 or higher (52.8 vs. 24.6%; p < 0.001). Tumor
DOI was higher in the END cohort (p < 0.001). Extracapsular
spread of nodal metastases was more often present in the END
cohort (p < 0.001). Median follow-up was longer for the END
cohort (p < 0.001).
Contralateral Regional Recurrences
The overall rate of CRR was 2.5% (20/816). Tumor DOI was
higher in patients who developed CRR (p < 0.001) (Table 2).
Vaso-invasive tumor growth was more frequently present in
patients who developed CRR (p = 0.032). END patients
developed CRR more often (14/365; 3.8%) as compared to SLNB
patients (6/451; 1.3%) (p = 0.021). None of the patients who
underwent bilateral END developed CRR. In one patient, CRR
was diagnosed in the presence of distant metastasis. CRR was
diagnosed in the presence of ipsilateral regional recurrence in one
END patient and in two SLNB patients. The rate of ipsilateral
nodal metastases, as detected by END or SLNB, was higher in
those who developed CRR (p = 0.018). None of the patients
in whom occult contralateral nodal metastases were detected
by SLNB or bilateral END (i.e., pN2c) developed CRR. Out
of those who developed CRR, 15 patients underwent salvage
treatment with curative intent; in three patients, no data on
salvage treatment was available.
Occult Contralateral Nodal Metastasis (i.e.,
pN2c and CRR)
The overall rate of occult contralateral nodal metastasis was
3.7% (30/816). Patients with paramedian tumors showed a higher
rate of contralateral nodal metastases compared to those with
lateralized tumors (p = 0.018) (Table 3). Tumor DOI was
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TABLE 1 | Patient and tumor characteristics comparing END and SLNB cohort.
N = 806 SLNB (n = 451) END (n = 365) P-value*
Age; mean (±SD) 62.03 (±11.97) 61.98 (±12.77) 0.960
Gender 0.533
Male (%) 233 (51.8%) 197 (54.0%)
Site of primary tumora <0.001†; 0.003†
Tongue (%) 300 (66.5%) 195 (53.4%)
Floor of Mouth (%) 98 (21.7%) 113 (31.0%)
Buccal Mucosa (%) 34 (7.5%) 35 (9.6%)
Other (%) 19 (4.3%) 22 (6.0%)
cT-stage <0.001†
T1 (%) 306 (67.8%) 133 (36.4%)
T2 (%) 145 (32.2%) 222 (63.6%)
pT-stageb <0.001†
T1 (%) 340 (75.4%) 172 (47.2%)
T2 (%) 107 (23.7%) 188 (51.5%)
T3 (%) 4 (0.9%) 3 (0.8%)
T4 (%) 0 (0%) 2 (0.5%)
DOI; mean (±SD) in
mm
5.32 (±4.28) 6.90 (±4.19) <0.001‡
pN-stage 0.533
pN0 (%) 347 (76.9%) 274 (75.1%)
pN+ (%) 104 (23.1%) 91 (24.9%)
pN2c 0.199
Yes (%) 8 (1.8%) 2 (0.5%)
ECS <0.001
Yes (%) 3 (0.7%) 32 (8.8%)
Follow-up in years;
median (IQR)
2.2 (1.0–4.1) 4.6 (2.5–7.3) <0.001}
SLNB sentinel lymph node biopsy, END elective neck dissection, SD standard deviation,
DOI depth of invasion, ECS extracapsular spread, IQR interquartile range.




‡ Independent samples t test.
Fisher’s exact test.
}Mann-Whitney U test.
aSignificance regarding tumors of the tongue and floor-of-mouth tumors.
bSignificance regarding tumors staged pT2 or higher.
higher in patients with occult contralateral nodal metastasis
(p < 0.002). Perineural tumor growth and vasoinvasive tumor
growth weremore often present in those with occult contralateral
nodal metastasis (p = 0.002, p = 0.001). A higher rate of
ipsilateral nodal metastases, as detected by SLNB or END, was
seen in patients with occult contralateral nodal metastasis (p =
0.025). Of those in whom occult contralateral nodal metastasis
was detected by either bilateral END or SLNB (i.e., pN2c),
ipsilateral nodal metastasis was simultaneously detected in three
patients (30%). No significant difference was seen in the rate
of occult contralateral nodal metastasis between the END and
SLNB cohort.
Survival
Figure 2 shows 5-year DSS for patients with and without occult
contralateral nodal metastasis (i.e., pN2c and CRR). Five-year
TABLE 2 | Characteristics associated with contralateral regional recurrence.
N = 816 No CRR (n = 796) CRR (n = 20) P-value*
Site of primary tumor 0.655
Tongue (%) 481 (60.4%) 14 (70.0%)
Floor of Mouth (%) 206 (25.9%) 5 (25.0%)
Buccal Mucosa (%) 68 (8.5%) 1 (5.0%)
Other (%) 41 (5.2%) 0 (0%)
pT-stagea 0.097
T1 (%) 503 (63.2%) 9 (45.0%)
T2 (%) 286 (35.9%) 9 (45.0%)
T3 (%) 5 (0.6%) 2 (10.0%)
T4 (%) 2 (0.3%) 0 (0%)
Location primary tumor 0.154
Lateralized 655 (97.4%) 18 (2.6%)
Paramedian 23 (92.0%) 2 (8.0%)
DOI; mean (±SD) in mm 5.90 (±4.21) 9.48 (±6.11) <0.001‡
Non-cohesive growth 0.316
Yes (%) 267 (53.6%) 13 (65.0%)
Perineural growth 0.071
Yes (%) 110 (18.8%) 7 (35.0%)
Vasoinvasive growth 0.032
Yes (%) 51 (8.9%) 5 (25.0%)
Procedure neckb 0.021†
SLNB (%) 445 (98.7%) 6 (1.3%)
Unilateral END (%) 323 (95.8%) 14 (4.2%)
Bilateral END (%) 28 (100%) 0 (0%)
pN-stage 0.018†
Ipsilateral pN+ (%) 179 (22.5%) 9 (45.0%)
pN2c N.A.
Yes (%) 10 (1.3%) 0 (0%)
ECS 0.588
Yes (%) 34 (4.3%) 1 (5.0%)
CRR contralateral regional recurrence, DOI depth of invasion, SD standard deviation,
SLNB sentinel lymph node biopsy, END elective neck dissection, ECS extracapsular
spread, N.A. not applicable.




‡ Independent samples t test.
Fisher’s exact test.
ap value regarding tumors staged pT1 vs. pT2 or higher.
bSignificance regarding difference in CRR rate between END and SLNB cohort.
DSS was significantly shorter for patients who developed CRR
as compared to patients without occult contralateral nodal
metastasis (42 vs. 92%, p < 0.001). No difference in 5-year DSS
was observed between those in whom occult contralateral nodal
metastasis were detected by SLNB or bilateral END (i.e., pN2c)
and patients without occult contralateral nodal metastasis (88
vs. 92%; p = 0.446). Five-year DSS of patients who developed
CRR was worse compared to those in whom occult contralateral
metastasis were detected by SLNB or bilateral END (i.e., pN2c),
although not statistically significant (42 vs. 88%; p = 0.066). Of
those who underwent salvage treatment with curative intent for
CRR, 67% (10/15) died of disease after an average follow-up of
6.1 months following occurrence of CRR.
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TABLE 3 | Characteristics associated with occult contralateral nodal metastasis
(i.e., pN2c and CRR).







Site of primary tumor 0.394
Tongue (%) 474 (60.3%) 21 (70.0%)
Floor of mouth (%) 203 (25.8%) 8 (26.7%)
Buccal mucosa (%) 68 (8.7%) 1 (3.3%)
Other (%) 41 (5.2%) 0 (0%)
pT-stagea 0.277
T1 (%) 496 (63.1%) 16 (53.3%)
T2 (%) 283 (36.0%) 12 (40.0%)
T3 (%) 5 (0.6%) 2 (6.7%)
T4 (%) 2 (0.3%) 0 (0%)
Location primary tumor 0.018
Lateralized 657 (96.2%) 26 (3.8%)
Paramedian 21 (84.0%) 4 (16.0%)
DOI; mean (±SD) in
mm
5.90 (±4.21) 8.46 (±5.75) 0.002‡
Non-cohesive growth 0.177
Yes (%) 262 (53.4%) 18 (66.7%)
Perineural growth 0.002†
Yes (%) 106 (18.3%) 11 (42.3%)
Vasoinvasive growth 0.001†
Yes (%) 49 (8.6%) 7 (28.0%)
Procedure neck 0.334
SLNB (%) 437 (98.7%) 14 (3.1%)
END (%) 349 (95.6%) 16 (4.4%)
pN-stagea 0.025†
Ipsilateral pN+ (%) 176 (22.4%) 12 (40.0%)
ECS 0.133
Yes (%) 32 (4.1%) 3 (10.0%)
CRR contralateral regional recurrence, DOI depth of invasion, SD standard
deviation, SLNB sentinel lymph node biopsy, END elective neck dissection, ECS
extracapsular spread.
*Bold script indicates significant value.
Fisher’s exact test.




ap-value regarding tumors staged pT1 vs. pT2 or higher.
Mean time of survival in patients who developed CRR was 4.1
years (95% CI 2.29–5.95), whereas mean time of survival of those
in whom contralateral nodal metastases were detected by SLNB
or bilateral END (i.e., pN2c) was 9.7 years (95% CI 7.37–12.02).
Themean time of survival in patients without occult contralateral
nodal metastasis was 19.3 years (95% CI 18.81–19.72).
Hazard for Developing CRR
Proportional hazard regression analysis showed that
patients who underwent END had a higher hazard for
developing CRR as compared to those who underwent
SLNB [HR = 2.922 (95% CI 1.11–7.71); p = 0.030]
(Figure 3). In addition, tumor DOI was significantly
associated with development of CRR as well [HR = 2.277
(95% CI 1.44–3.60); p < 0.001].
DISCUSSION
This is the first study that evaluated incidence and hazard of CRR
in early-stage OSCC not involving the midline (i.e., lateralized
and paramedian) and compared these outcomes between patients
who underwent either END or SLNB.
The overall incidence of occult contralateral nodal metastasis
in this study was 3.7% (30/816), which is in concordance with
the reported incidence of occult contralateral nodal metastasis in
lateralized early-stage OSCC [2.7% (95% CI 1.2–4.2%)] (8, 9, 14,
16–21).
Our results showed higher incidence of CRR in patients who
underwent END (3.8%) as compared to those who underwent
SLNB (1.3%) (p = 0.018). Furthermore, our data showed that
patients staged by END had a higher hazard of developing CRR,
independent of factors such as tumor DOI, compared to patients
staged by SLNB [HR= 2.922 (95% CI 1.11–7.71); p= 0.030].
Five-year DSS of patients who developed CRR was poor in
our population, in particular when compared to those without
occult contralateral nodal metastasis. These findings are in line
with previous reports on prognosis of (lateralized) OSCC patients
with CRR (16, 23, 24). Moreover, our results suggest that 5-year
DSS of patients in whom contralateral nodal metastases were
detected at an earlier stage by SLNB or bilateral END (pN2c)
may be better than in those who eventually developed CRR. In
addition, the successful salvage rate of those who developed CRR
was only 33% in our population. This highlights the importance
of adequate staging or treatment of the contralateral clinically
negative neck.
Nevertheless, elective treatment of the contralateral clinically
negative neck in OSCC without midline involvement remains
controversial. This controversy is sustained by the varying
incidence of occult contralateral nodal metastasis and CRR
among institutions and the accompanying morbidity of
(bilateral) END (18–20, 23, 24, 31–34). In our population,
only two patients who underwent bilateral END had occult
contralateral nodal metastasis, indicating that 26/28 patients
(93%) underwent unnecessary contralateral END. With this
in mind, it is worth noting that SLNB has the benefit of
staging the contralateral clinically negative neck simultaneous
with the ipsilateral neck. Accordingly, SLNB is able to
avoid overtreatment of the contralateral neck by allowing
accurate selection of only those that require treatment of the
contralateral neck.
Another predictor for development of CRR in our population
was tumor DOI [HR = 2.277 (95% CI 1.44–3.60); p <
0.001], which is in agreement with previous findings by Ganly
et al. (35). In their study, neck failure in the undissected
contralateral neck of T1-2N0 oral tongue patients accounted
for 39% of all recurrences. Moreover, their results showed
that tumor thickness was predicting for CRR. Although
tumor thickness and DOI are not equivalent, they have
similar prognostic implications for nodal metastases (36). As
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FIGURE 2 | Five-year DSS curves for lateralized or paramedian early-stage OSCC patients without contralateral occult nodal metastasis (blue bold line) as compared
to those with contralateral occult nodal metastasis: initially staged pN2c by SLNB or bilateral END (red interrupted line) or CRR (green line).
FIGURE 3 | Cumulative hazard curve regarding development of CRR in patients with early-stage OSCC not involving the midline, divided by initial management of the
neck: elective neck dissection (END; red bold line) or sentinel lymph node biopsy (SLNB; blue interrupted line). A significantly higher hazard for developing CRR was
observed for patients who underwent END compared to those who underwent SLNB [HR = 2.922 (95% CI 1.11–7.71)].
a consequence, the higher rate of CRR in our END cohort
may be explained by greater tumor DOI in these patients.
Nevertheless, when correcting for DOI in our proportional
hazard regression analysis, a significantly higher hazard for
developing CRR was observed in END patients as compared to
SLNB patients.
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The limitations of our study remain its retrospective design
and the heterogeneity in performing SLNB or END among
institutions. Secondly, occult contralateral nodal metastases are
uncommon in this population, which irrevocably results in a
small number of events for analyses. Accordingly, it could be
argued that a larger sample, resulting in more CRR and pN2c
events for analyses, may result in a significantly better prognosis
for those in whom the metastatic involved contralateral neck is
correctly staged and treated at an earlier stage, as compared to
those who eventually develop CRR. Thirdly, since END patients
were included between 1990 and 2015, a substantial proportion
may have been elected for END based on potentially dated
therapeutic guidelines or aged diagnostic imaging modalities.
Moreover, patients were predominantly selected for END based
on estimated tumor DOI >4mm, inevitably resulting in higher
tumor DOI in the END cohort. Due to this heterogeneity in
therapeutic decision making between both cohorts, they cannot
easily be compared, especially since the END cohort had a
higher tumor DOI, higher T-stages, a higher rate of extracapsular
spread of nodal metastases, and a longer follow-up duration,
which might impact the occurrence of occult contralateral
nodal metastasis or CRR. Nevertheless, there was no significant
difference in the total rate of occult contralateral nodal metastasis
(i.e., pN2c and CRR) between both cohorts, which implies
that these cohorts can be compared when concerning control
of the contralateral clinically negative neck. Furthermore, our
proportional hazard regression analysis, which allows adjustment
for confounding effects of included variables, showed a higher
hazard for developing CRR in the END cohort, independent of
confounding factors such as tumor DOI. In addition, both higher
T-stages and presence of extracapsular spread of nodal metastases
showed no association with contralateral nodal metastases or
CRR in our univariate analyses. Besides, although a longer follow-
up was available for END patient compared to SLNB patients,
local or regional recurrences are uncommon after 2 years post-
treatment (37). The follow-up duration of the SLNB cohort was
therefore considered long enough for missed occult metastases
to become clinically manifest and provides no explanation for
the difference in rate of CRR between both cohorts. It could be
argued that patients who underwent unilateral END for tumors
from which the specific location was missing should be excluded
from this study. However, since none of these patients developed
CRR, excluding themwould result in a relatively higher incidence
of CRR in the END cohort, which will presumably induce a
distortion of results in favor of SLNB. Fourthly, as there are no
clear guidelines in which cases to perform contralateral END
in early-stage OSCC, these were likely performed based on
preference of the treating physician and on availability of the
latest state-of-the-art imaging modalities. This may introduce
some bias; however, it reflects daily clinical practice at that
time. This strengthens the need for more research to develop
evidence-based guidelines on this important topic. Fifthly, in
this study, the 7th TNM classification was applied, whereas the
8th edition has already been implemented (38). While tumor
diameter reflected pT-stage in the 7th edition, DOI is newly
incorporated for T-stage in the 8th edition (36, 39). Due to
missing data on DOI in several cases, our results could not be
directly translated to the 8th TNM classification. Finally, some
clinical and histopathological factors that have been associated
with contralateral nodal metastasis in OSCC were not included
due to lack of data. These factors include histological grading,
surgical margin status, peritumoral inflammation, (adjuvant)
radiotherapy to contralateral neck, and time of initial diagnosis
(24). In particular, (adjuvant) radiotherapy to contralateral neck
could influence the occurrence of CRR in these patients and
should therefore be documented and incorporated in further
studies. Although non-cohesive growth of the tumor was
included as a potential predictor for CRR in our analyses, it was
not subdivided by grading of pattern of invasion (i.e., cohesive
growth, small islands, thin strands, and individual tumor cells)
(24, 40). Nevertheless, the correlation between several of these
factors (i.e., histological grading, peritumoral inflammation,
and pattern of invasion) and contralateral nodal metastasis is
dubious (24).
In conclusion, the incidence of CRR in lateralized or
paramedian early-stage OSCC is relatively low (2.5%). As the
salvage rate and prognosis of those who develop CRR remain
poor, adequate staging of the contralateral clinically negative
neck is highly recommended, especially since the prognosis
of those in whom occult contralateral nodal metastases are
detected at an earlier stage may be favorable compared to
those who eventually develop CRR. In our population, a higher
incidence of CRR was observed in those who underwent
END for lateralized or paramedian early-stage OSCC, as
compared to those who underwent SLNB. Furthermore, a
higher hazard for developing CRR was observed in patients
who underwent END in a clinical setting as compared to
patients who underwent SLNB. Accordingly, our data suggest
that SLNB allows for better control of the contralateral
clinically negative neck in early-stage OSCC not involving
the midline.
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